Study reports benefits of aspirin plus Plavix
This article was originally published in The Tan Sheet
Executive Summary
A study shows patients with atrial fibrillation reduced their risk of major vascular events by 11 percent by taking Plavix (clopidogrel) plus aspirin compared to aspirin alone. The results "suggest a potential change in clinical practice," says a study investigator. Findings announced March 31 from the ACTIVE A (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Cardiovascular Events) phase III double-blind, placebo-controlled trial also said the heart arrhythmia patients taking the antiplatelet drug and aspirin saw a 28 percent reduction in stroke during the median 3.6 years of follow-up. Bristol-Myers Squibb and Sanofi-Aventis, which jointly market Plavix, sponsored the study. Atrial fibrillation patients have a five-fold greater stroke risk and cannot take oral anticoagulants, a researcher said. A 2007 analysis found aspirin alone is more effective than Plavix and other Rx antiplatelets in preventing first or repeat heart attack or stroke (1"The Tan Sheet" April 23, 2007, p. 10)
You may also be interested in...
Aspirin Tops Three Rx Drugs In Preventing Heart Attack – Consumers Union
Aspirin is the blood thinning agent of choice over three prescription antiplatelet medications for preventing first or repeat heart attack or stroke, according to a Consumers Union report
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.